Meg Begur

Cooley advised Kimia Therapeutics on its $55 million Series A financing. Partner Josh Seidenfeld led the Cooley team advising Kimia Therapeutics, which is a drug discovery platform that uncovers novel biological insights through precision chemistry and machine learning.

Read more

Cooley advised Biote, a medical practice-building business within the hormone optimization space, on its definitive business combination agreement with special purpose acquisition company (SPAC) Haymaker Acquisition Corp III. Lawyers Michal Berkner and Jarrett Burks led the Cooley team advising Biote.

Cooley advised Exscientia, an AI-driven pharmatech company based in Oxford, United Kingdom, on its $510.4 million initial public offering, including concurrent private placements to SoftBank and the Bill & Melinda Gates Foundation. Partners David Boles, Claire Keast-Butler, Div Gupta and Marc Recht led the Cooley team advising Exscientia.

Cooley advised Freshworks, a leading software company empowering businesses to delight their customers and employees, on its $1.1286 billion initial public offering of shares of Class A common stock. Lawyers Jon Avina, Dave Segre, Calise Cheng and Sepideh Mousakhani led the Cooley team advising Freshworks.

Cooley advised C3.ai on its $748.65 million initial public offering of 17,825,000 shares of Class A common stock , which includes the full exercise of the underwriters’ option to purchase additional shares. C3.ai, whose securities now trade on the New York Stock Exchange under the symbol AI, is an enterprise artificial intelligence company. Partners Eric Jensen and Calise Cheng led the Cooley team.